Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 1, 2000, Pages 7-13

  Costantini, V ^a   Deveglia, R ^a   Stabile, A ^a   Nenci, Giuseppe G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antithrombotic activity; Glycosaminoglycans; Heparin; Pharmacokinetics; Radiolabeled heparin; Vessel wall

Indexed keywords

BLOOD CLOTTING FACTOR 10A; GLYCOSAMINOGLYCAN; HEPARIN; IODINE 125;

ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DISTRIBUTION; GASTROINTESTINAL ABSORPTION; HEPARINIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RAT; VEIN THROMBOSIS;

EID: 0033952724     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200001000-00002     Document Type: Article

References (28)

1. 1. Hirsh J. Heparin. N Engl J Med 1991; 324:1565-1574.
2. 2. Nenci GG, Agnelli G. Clinical experience with low molecular weight heparins. Thrombos Res 1990; 56(suppl 11): 69-87.
3. 3. Thomas DP. Heparin in the prophylaxis and treatment of venous thromboembolism. Semin Hematol 1978; 15:1-12.
4. 4. Fisher A, Astrup T. Administration of heparin by mouth. Proc Soc Exp Biol Med 1939; 42; 81-88.
5. 5. Doutremepuich C, Toulemonde F, Lormeau JC. Oral administration of low molecular weight heparin fraction in rabbits. Semin Thromb Hemost 1985; 11: 323-325.
6. 6. Koh TY, Bacharicha KR. Intestinal absorption of stable heparinic acid complexes. J Lab Clin Med 1972; 80: 47-55.
7. 7. Sue TK, Jaques LB, Yuen E. Effect of acidity, cations and alcoholic fraction on absorption of heparin from gastrointestinal tract. Can J Physiol Pharmacol 1976; 54:613-618.
8. 8. Larsen AK, Lund DP, Langer R, Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci USA 1986; 83: 2964-2968.
9. 9. Jaques LB, Hiebert LM, Wice SM. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000. J Lab Clin Med 1991; 117:122-130.
10. 10. Bick RL, Ross ES. Clinical use of intrapulmonary heparin. Semin Thromb Hemost 1985; 11: 213-217.
11. 11. Ahmed T, Garrico J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. New Engl J Med 1993; 329: 90-95.
12. 12. Dunn JM, Hollister AS. Oral bioavailability of heparin using a novel delivery system. Curr Ther Res 1995; 56: 738-745.
13. 13. Andriuoli G, Bossi M, Caramazza I, Zoppetti G. Heparin by alternative routes of administration. Haemostasis 1990; 20(suppl 1): 154-158.
14. 14. Pescador R, Diamantini G, Mantovani M, Malandrino S, Riva A, Casu B, et al. Absorption by rat intestinal tract of fluorescein-labelled pig duodenal glycosaminoglycans. Arzneim-Forsch 1980; 30: 1893-1896.
15. 15. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 1998; 98: 1610-1615.
16. 16. Sgagnoli I, Fumagalli G, Andriuoli G. Anticoagulant and antithrombotic activity of heparin salts by intraduodenal route in rabbits. Thromb Res 1992; 68:195-200.
17. 17. Marchi E, Barbanti M, Milani R, Breccia A, Fini A, Gattavecchia E. Organ glycosaminoglycan distribution after intravenous and oral administration in rats. Sem Thromb Hemost 1994; 20: 297-300.
18. 18. Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulphate administered to man. Studies using radioiodinated derivative. Thromb Haemost 1989; 62: 945-949.
19. 19. Volpi N. Physico-chemical properties and the structure of dermatan sulfate fractions purified from plasma after oral administration in healthy human volunteers. Thromb Haemost 1996; 75: 491-496.
20. 20. Reyers I, Mysliwiec M, Mussoni L, Donati MB. Stasis-induced venous thrombosis. In: Breddin K, Zimmerman R (editors): Angiological Symposium Kitzbuhel. Standardization of animal models of thrombosis Vol 17. Stuttgart: Schauttuer; 1983. pp. 99-104.
21. 21. Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860.
22. 22. Hatton MWC, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-670.
23. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123.
24. 24. Wells XE, Dawes J. Role of the liver and kidney in the desulphatation of heparin in vivo. Thromb Haemost 1995; 74:667-672.
25. 25. Young E, Horner AA. The assay and partial characterization of macromolecular heparin depolymerase activity in rat small intestine. Biochem J 1979; 180: 587-596.
26. 26. Dawes J, Pepper DS. Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost 1992; 67: 468-472.
27. 27. Torri G, Bisio A, Casu B, Guerrini M, Naggi A, Nogueira Barbosa MC, et al. Nuclear magnetic resonance analysis of human urine: influence of intravenous and oral administration of glycosaminoglycans. Semin Thromb Hemost 1994; 20: 144-151.
28. 28. Hiebert L, Wice S. Antithrombotic of oral heparins in a rat model [abstract]. Thromb Haemost 1997; (suppl): PS-1212.